| Ticker: VGINF | 700 Bay Street, Suite 1000 | |
| Exchange: NASDAQ-National Market | Toronto, Foreign M5G 1 Z6 | |
| Industry: Manufacturing | (416) 813-3240 |
| Type of Shares: | Common Shares | Filing Date: | 4/2/96 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 6/18/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $11.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.81 | |
| Offering Amount: | $30,000,000 | Selling: | $0.48 | |
| Expenses: | $895,000 | Reallowance: | $0.10 | |
| Shares Out After: | 6,937,200 |
| Manager | Tier | Phone |
| Gerard Klauer Mattison & Company, Incorporated | Lead Manager | (212) 481-6030 |
| First Marathon Securities Limited | Co-manager | (416) 869-3707 |
| Auditor: Price Waterhouse | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/96 | |||
| Revenue: | $0.00 | $0.00 | Assets: | $2.17 | |
| Net Income: | -$2.72 | -$1.02 | Liabilities: | $2.21 | |
| EPS: | -$0.59 | -$0.20 | Equity: | -$0.04 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company has developed a proprietary integrated genetic diagnostic system and proprietary application-based products that can quickly identify gene sequences and disease-associated genetic mutations. The company's OpenGene System is based upon The company's proprietary, ultra-thin electrophoretic gel cassette technology and includes a low-cost, high speed DNA sequencer, related equipment and consumables, and software designed for specific test kits that rely on the company's proprietary stratified matrix testing method to identify disease-associated mutations. The company has filed 20 U.S. patent applications covering various components of its sequencing system, technology and related application-based products, one of which has been issued, two of which have been allowed and one of which has received an indication of allowed claims. |
| Use of Proceeds |
| The proceeds from the offering will be used for research and development, of a marketing and sales organization, development of manufacturing operations, debt repayment, and for general corporate purposes, including working capital. |
©1996 IPO Data Systems, Inc. - All rights reserved.